The Analysis of Key Factors Related to ADCs Structural Design

Antibody–Drug Conjugates for Cancer Treatment

(2018) John M. Lambert et al.   Annual Review of Medicine

Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody–Drug Conjugates with Phenol-Containing Payloads

(2018) Donglu Zhang et al.   BIOCONJUGATE CHEMISTRY

FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates

(2018) Byoung-Chul Lee et al.   BIOCONJUGATE CHEMISTRY

Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1

(2018) Jun Lai et al.   BIOMATERIALS

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker

(2018) Peter S. Dragovich et al.   CHEMISTRY-A EUROPEAN JOURNAL

Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy

(2018) Hadi Nasiri et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor

(2018) Ryo Tsumura et al.   JOURNAL OF CONTROLLED RELEASE

Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol

(2018) Hoda E. Mohamed et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

(2018) Yelena Kovtun et al.   MOLECULAR CANCER THERAPEUTICS

Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates

(2018) Donglu Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models

(2018) Patrick J. Burke et al.   MOLECULAR CANCER THERAPEUTICS

Bispecific antibodies for cancer therapy: A review

(2018) Anuradha Krishnamurthy et al.   PHARMACOLOGY & THERAPEUTICS

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

(2018) Yasuaki Anami et al.   Nature Communications

Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

(2018) Raffaella Rossin et al.   Nature Communications

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody–Drug Conjugates

(2018) Zhonghua Pei et al.   MOLECULAR PHARMACEUTICS

Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates

(2017) Martin Pabst et al.   JOURNAL OF CONTROLLED RELEASE

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

(2017) Julian Andreev et al.   MOLECULAR CANCER THERAPEUTICS

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

(2017) Elie Dheilly et al.   MOLECULAR THERAPY

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

(2017) Ruogu Qi et al.   Nature Communications

Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers

(2017) Carl U. Bialucha et al.   Cancer Discovery

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

Linkers Having a Crucial Role in Antibody–Drug Conjugates

(2016) Jun Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

(2016) Elizabeth A. Kuczynski et al.   JNCI-Journal of the National Cancer Institute

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

(2016) Patrick J. Burke et al.   MOLECULAR CANCER THERAPEUTICS

Recent advances in the construction of antibody–drug conjugates

(2016) Vijay Chudasama et al.   Nature Chemistry

Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody–Drug Conjugates

(2016) Donglu Zhang et al.   ACS Medicinal Chemistry Letters

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

(2016) Elizabeth A. Kuczynski et al.   JNCI-Journal of the National Cancer Institute

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

(2015) K. J. Hamblett et al.   CANCER RESEARCH

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

(2015) A. V. Yurkovetskiy et al.   CANCER RESEARCH

Antibody-targeted drugs and drug resistance—Challenges and solutions

(2015) LeeRon Shefet-Carasso et al.   DRUG RESISTANCE UPDATES

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

(2015) Marc Damelin et al.   PHARMACEUTICAL RESEARCH

Abstract 4470: Elucidating the role of drug-linker hydrophobicity in the disposition of antibody-drug conjugates

(2015) Svetlana O. Doronina et al.   CANCER RESEARCH

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

A new dawn for gemtuzumab ozogamicin?

(2014) Mohamed A Kharfan-Dabaja   LANCET ONCOLOGY

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Antibody-drug conjugates

(2013) Alain Beck et al.   mAbs

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors

(2012) Y. Pak et al.   CANCER RESEARCH

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Brentuximab vedotin

(2012) Anas Younes et al.   NATURE REVIEWS DRUG DISCOVERY

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage

(2011) Brenda A. Kellogg et al.   BIOCONJUGATE CHEMISTRY

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

(2011) A Palumbo et al.   BRITISH JOURNAL OF CANCER

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers

(2011) Carlee E. Ashley et al.   NATURE MATERIALS

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

(2010) Y. V. Kovtun et al.   CANCER RESEARCH

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters

(2008) E. A. Dubikovskaya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH